Your browser doesn't support javascript.
loading
A differential response to sunitinib: sustained systemic response paralleled by intra-dural progression in the spine. Should standard response criteria be reviewed?
Jafri, Mariam; Porfiri, Emilo.
Afiliación
  • Jafri M; University Hospital Birmingham Foundation Trust, Queen Elizabeth Hospital, Birmingham, UK. mariam.jafri@uhb.nhs.uk
Clin Genitourin Cancer ; 7(2): E42-4, 2009 Aug.
Article en En | MEDLINE | ID: mdl-19692324
Orally available tyrosine kinases have revolutionized the treatment of renal cell carcinoma. These agents have impressive response rates compared with interferon and also have a cytostatic effect. We describe a case of a patient treated predominantly with continuous sunitinib who had a good partial response to sunitinib in the lungs, liver, adrenal gland, and lymph nodes but dural progression. We describe prolonged sustained response achieved by continuing sunitinib despite dural progression. This case demonstrates that standard treatment criteria may need reviewing.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pirroles / Neoplasias de la Columna Vertebral / Inhibidores de la Angiogénesis / Indoles / Antineoplásicos Límite: Humans / Male / Middle aged Idioma: En Revista: Clin Genitourin Cancer Asunto de la revista: NEOPLASIAS / UROLOGIA Año: 2009 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pirroles / Neoplasias de la Columna Vertebral / Inhibidores de la Angiogénesis / Indoles / Antineoplásicos Límite: Humans / Male / Middle aged Idioma: En Revista: Clin Genitourin Cancer Asunto de la revista: NEOPLASIAS / UROLOGIA Año: 2009 Tipo del documento: Article Pais de publicación: Estados Unidos